Journal Citation Reports
Journal Citation Reports (JCR) is a product of Clarivate Analytics and is an authoritative resource for bibliometric and citation analysis. It provides a systematic, objective means to critically evaluate the world's leading scientific journals and their impact and influence in the global research community.
Overview
Journal Citation Reports provides a comprehensive overview of the world's most influential academic journals. It uses a combination of impact factor, immediacy index, and other key metrics to provide a snapshot of the influence and importance of a journal in its field. JCR is used by academic institutions, publishers, and researchers to evaluate and compare journals, and to understand their relative importance in the global research community.
History
The first edition of the Journal Citation Reports was published in 1975 by the Institute for Scientific Information (ISI). It was initially a part of ISI's Science Citation Index (SCI), but later became a separate product. In 2016, Clarivate Analytics acquired the product from Thomson Reuters.
Metrics
Journal Citation Reports uses several metrics to evaluate and rank journals. The most well-known of these is the Impact Factor, which measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. Other metrics used by JCR include the Immediacy Index, which measures how quickly articles in a journal are cited, and the Eigenfactor Score, which considers the number of times articles from the journal published in the past five years have been cited in the JCR year.
Criticism
Despite its widespread use, Journal Citation Reports has been criticized for its over-reliance on the Impact Factor. Critics argue that the Impact Factor can be manipulated and does not accurately reflect the quality of individual articles. In response to these criticisms, Clarivate Analytics has introduced additional metrics in JCR, such as the Eigenfactor Score and the 5-Year Impact Factor.
See also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
